
In ocular myasthenia gravis (OMG), early prednisolone initiation (within 6 months) and higher pyridostigmine doses were associated with achieving minimal manifestation (MM). Of the 101 OMG patients, 80.2% achieved MM. Prednisolone dosage and presence of AChRAb or thymoma were not linked to MM. Early treatment strategies and adjusted pyridostigmine doses play a critical role in patient outcomes.
Like
Save
Share